Gene

Microsatellite

Biology

Chromatin remodeling

Mutation

Cancer research

SWI/SNF

Pancreatic cancer

Microsatellite instability

SMARCB1

Biomarker

Genetics

Chromatin

ARID1A

Internal medicine

SMARCA4

Oncology

Medicine

Immunotherapy

Allele

Cancer

JCI Insight

BACKGROUND. Immune checkpoint inhibitors (ICIs) fail to demonstrate efficacy in pancreatic cancer. Recently, genomic biomarkers have been associated with response to ICIs: microsatellite instability high (MSI-H) and tumor mutation burden (TMB) > 10 mutations/Mb. Alterations in Switch/Sucrose Nonfermentable (SWI/SNF) chromatin remodeling genes may predispose to improved outcomes with immunotherapy. The current study examined a possible role for SWI/SNF complex abnormalities in pancreatic cancer responsiveness to ICIs.

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer